Wedbush raised the firm’s price target on Neurocrine (NBIX) to $130 from $115 and keeps an Outperform rating on the shares. The firm notes the company reported a narrow Ingrezza beat in Q1. However, the more notable result was the Crenessity revenue beat in its first full quarter of launch. While it remains early days, the company reported that 413 total patient enrollment forms have been received thus far. Additionally, the split appears slightly more tilted towards pediatric CAH patients, Wedbush adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $145 from $137 at RBC Capital
- Promising Growth Trajectory for Neurocrine: Buy Rating Justified by Strong Drug Performance and Innovative Trials
- Neurocrine price target raised to $152 from $137 at UBS
- Neurocrine price target raised to $165 from $155 at Guggenheim
- Neurocrine price target raised to $183 from $179 at BofA
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue